𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I Study of Eniluracil, Oral 5-Fluororacil and Gemcitabine in Patients with Advanced Malignancy

✍ Scribed by Sherry Morgan-Meadows; James P. Thomas; Daniel Mulkerin; Jordan D. Berlin; Howard Bailey; Kim Binger; Jennifer Volkman; Dona Alberti; Chris Feierabend; Rebecca Marrocha; Rhoda Z. Arzoomanian; George Wilding

Book ID
110398227
Publisher
Springer US
Year
2002
Tongue
English
Weight
63 KB
Volume
20
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I study of pegylated liposomal dox
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies
✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie

Phase I study of eniluracil and oral 5-f
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma
✍ Edgardo Rivera; Vicente Valero; Massimo Cristofanilli; Debra K. Frye; Daniel J. πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 66 KB πŸ‘ 2 views

## Abstract ## PURPOSE The authors conducted a single‐institution Phase I clinical trial to determine the maximum tolerated doses and to define the toxic effects of oral eniluracil and oral 5‐fluorouracil (5‐FU) combined with docetaxel in patients with metastatic breast carcinoma. ## PATIENTS AND